Advances in adenovirus-mediated p53 cancer gene therapy

Expert Opinion on Biological Therapy

Volumn 13, Issue 11, 2013, Pages 1569-1583

  Tazawa, Hiroshi ^a,b   Kagawa, Shunsuke ^b   Fujiwara, Toshiyoshi ^b  

^a OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Adenovirus; Cancer; Gene therapy; P53

Indexed keywords

ADENOVIRUS VECTOR; CARBOPLATIN; CISPLATIN; CONDITIONALLY REPLICATING ADENOVIRUS; CONTUSUGENE LADENOVEC; E1A PROTEIN; GENDICINE; METHOTREXATE; MICRORNA; NAVELBINE; OBP 301; OBP 702; PACLITAXEL; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; SCH 58500; SG600 P53; TELOMELYSIN; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BYSTANDER EFFECT; CANCER GENE THERAPY; CANCER INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEVER; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LIVER CELL CARCINOMA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; NONHUMAN; OVARY CANCER; P53 GENE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; VIRAL GENE THERAPY; WILD TYPE;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ADENOVIRUS E1B PROTEINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BYSTANDER EFFECT; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE EXPRESSION REGULATION, VIRAL; GENES, P53; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MICRORNAS; NEOPLASMS; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TRANSGENES; TUMOR SUPPRESSOR PROTEIN P53; VIRUS REPLICATION;

EID: 84885615897     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.845662     Document Type: Article

References (100)

1. Roth JA, Cristiano RJ. Gene therapy for cancer: What have we done and where are we going? J Natl Cancer Inst 1997á89:21-39
2. Vousden KH, Prives C. Blinded by the light: The growing complexity of p53. Cell 2009á137:413-31
3. Olivier M, Eeles R, Hollstein M, et al. The IARC TP53 database: New online mutation analysis and recommendations to users. Hum Mutat 2002á19:607-14
4. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: Origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010 2:a001008
5. Ognjanovic S, Olivier M, Bergemann TL, Hainaut P. Sarcomas in TP53 germline mutation carriers: A review of the IARC TP53 database. Cancer 2012á118:1387-96
6. Malkin D. Li-fraumeni syndrome. Genes Cancer 2011á2:475-84
7. Gasco M, Crook T. p53 family members and chemoresistance in cancer: What we know and what we need to know. Drug Resist Updat 2003á6:323-8
8. Roth JA, Swisher SG, Meyn RE. p53 tumor suppressor gene therapy for cancer. Oncology (Williston Park) 1999á13:148-54
9. Fang B, Roth JA. Tumor-suppressing gene therapy. Cancer Biol Ther 2003á2:S115-21
10. Zhang WW, Fang X, Mazur W, et al. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1994á1:5-13
11. Fujiwara T, Grimm EA, Mukhopadhyay T, et al. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994á54:2287-91
12. Liu TJ, Zhang WW, Taylor DL, et al. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 1994á54:3662-7
13. Liu TJ, el-Naggar AK, McDonnell TJ, et al. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res 1995á55:3117-22
14. Clayman GL, el-Naggar AK, Roth JA, et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 1995á55:1-6
15. Gomez-Manzano C, Fueyo J, Kyritsis AP, et al. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res 1996á56:694-9
16. Kock H, Harris MP, Anderson SC, et al. Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo. Int J Cancer 1996á67:808-15
17. Lang FF, Yung WK, Sawaya R, Tofilon PJ. Adenovirus-mediated p53 gene therapy for human gliomas. Neurosurgery 1999á45:1093-104
18. Santoso JT, Tang DC, Lane SB, et al. Adenovirus-based p53 gene therapy in ovarian cancer. Gynecol Oncol 1995á59:171-8
19. Mujoo K, Maneval DC, Anderson SC, Gutterman JU. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene 1996á12:1617-23
20. Pagliaro LC, Keyhani A, Liu B, et al. Adenoviral p53 gene transfer in human bladder cancer cell lines: Cytotoxicity and synergy with cisplatin. Urol Oncol 2003á21:456-62
21. Hamada K, Alemany R, Zhang WW, et al. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res 1996á56:3047-54
22. Spitz FR, Nguyen D, Skibber JM, et al. In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. Anticancer Res 1996á16:3415-22
23. Shimada H, Shimizu T, Ochiai T, et al. Preclinical study of adenoviral p53 gene therapy for esophageal cancer. Surg Today 2001á31:597-604
24. Gabrilovich DI. INGN 201 (Advexin): Adenoviral p53 gene therapy for cancer. Expert Opin Biol Ther 2006á6:823-32
25. Shi J, Zheng D. An update on gene therapy in China. Curr Opin Mol Ther 2009á11:547-53
26. Wills KN, Maneval DC, Menzel P, et al. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther 1994á5:1079-88
27. Fujiwara T, Kataoka M, Tanaka N. Adenovirus-mediated p53 gene therapy for human cancer. Mol Urol 2000á4:51-4
28. Roth JA. Adenovirus p53 gene therapy. Expert Opin Biol Ther 2006á6:55-61
29. Lane DP, Cheok CF. Lain S. p53-based cancer therapy. Cold Spring Harb Perspect Biol 2010 2:a001222
30. Zhang WW, Alemany R, Wang J, et al. Safety evaluation of Ad5CMV-p53 in vitro and in vivo. Hum Gene Ther 1995á6:155-64
31. Nishizaki M, Meyn RE, Levy LB, et al. Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo. Clin Cancer Res 2001á7:2887-97
32. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012á62:10-29
33. Mogi A, Kuwano H. TP53 mutations in nonsmall cell lung cancer. J Biomed Biotechnol 2011á2011:583929
34. Schuler M, Rochlitz C, Horowitz JA, et al. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum Gene Ther 1998á9:2075-82
35. Swisher SG, Roth JA, Nemunaitis J, et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999á91:763-71
36. Fujiwara T, Tanaka N, Kanazawa S, et al. Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. J Clin Oncol 2006á24:1689-99
37. Nemunaitis J, Swisher SG, Timmons T, et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 2000á18:609-22
38. Schuler M, Herrmann R, De Greve JL, et al. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: Results of a multicenter phase II study. J Clin Oncol 2001á19:1750-8
39. Swisher SG, Roth JA, Komaki R, et al. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 2003á9:93-101
40. Gregoire V, Lefebvre JL, Licitra L, Felip E. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010 21(Suppl 5):v184-6
41. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004á350:1937-44
42. Clayman GL, el-Naggar AK, Lippman SM, et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998á16:2221-32
43. Clayman GL, Frank DK, Bruso PA, Goepfert H. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res 1999á5:1715-22
44. Nemunaitis J, Clayman G, Agarwala SS, et al. Biomarkers predict p53 gene therapy efficacy in recurrent squamous cell carcinoma of the head and neck. Clin Cancer Res 2009á15:7719-25
45. Nemunaitis J. Head and neck cancer: Response to p53-based therapeutics. Head Neck 2011á33:131-4
46. Peng Z. Current status of gendicine in China: Recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005á16:1016-27
47. Zhang S, Li Y, Li L, et al. Phase I study of repeated intraepithelial delivery of adenoviral p53 in patients with dysplastic oral leukoplakia. J Oral Maxillofac Surg 2009á67:1074-82
48. Ohgaki H, Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 2009á100:2235-41
49. Lang FF, Bruner JM, Fuller GN, et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: Biological and clinical results. J Clin Oncol 2003á21:2508-18
50. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet 2013á381:400-12
51. Wagata T, Shibagaki I, Imamura M, et al. Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas. Cancer Res 1993á53:846-50
52. Shimada H, Matsubara H, Shiratori T, et al. Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma. Cancer Sci 2006á97:554-61
53. Sah NK, Munshi A, Nishikawa T, et al. Adenovirus-mediated wild-type p53 radiosensitizes human tumor cells by suppressing DNA repair capacity. Mol Cancer Ther 2003á2:1223-31
54. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003á362:1907-17
55. Hsu IC, Metcalf RA, Sun T, et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991á350:427-8
56. Oda T, Tsuda H, Scarpa A, et al. p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res 1992á52:6358-64
57. Yang ZX, Wang D, Wang G, et al. Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma. J Cancer Res Clin Oncol 2010 136:625-30
58. Ylosmaki E, Hakkarainen T, Hemminki A, et al. Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA. J Virol 2008á82:11009-15
59. Cawood R, Chen HH, Carroll F, et al. Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells. PLoS Pathog 2009á5:e1000440
60. Sugio K, Sakurai F, Katayama K, et al. Enhanced safety profiles of the telomerase-specific replication-competent adenovirus by incorporation of normal cell-specific microRNA-targeted sequences. Clin Cancer Res 2011á17:2807- 18
61. Vaughan S, Coward JI, Bast RC Jr, et al. Rethinking ovarian cancer: Recommendations for improving outcomes. Nat Rev Cancer 2011á11:719-25
62. Kupryjanczyk J, Thor AD, Beauchamp R, et al. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 1993á90:4961-5
63. Wolf JK, Bodurka DC, Gano JB, et al. A phase I study of Adp53 (INGN 201á ADVEXIN) for patients with platinumand paclitaxel-resistant epithelial ovarian cancer. Gynecol Oncol 2004á94:442-8
64. Buller RE, Runnebaum IB, Karlan BY, et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 2002á9:553-66
65. Buller RE, Shahin MS, Horowitz JA, et al. Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500. Cancer Gene Ther 2002á9:567-72
66. Shah JB, McConkey DJ, Dinney CP. New strategies in muscle-invasive bladder cancer: On the road to personalized medicine. Clin Cancer Res 2011á17:2608-12
67. Gao J, Huang HY, Pak J, et al. p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis. Oncogene 2004á23:687-96
68. Pagliaro LC, Keyhani A, Williams D, et al. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: A phase I study of p53 gene therapy. J Clin Oncol 2003á21:2247-53
69. Kuball J, Wen SF, Leissner J, et al. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J Clin Oncol 2002á20:957-65
70. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993á75:817-25
71. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995á80:293-9
72. Crighton D, Wilkinson S, O'Prey J, et al. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006á126:121-34
73. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J 1993á12:461-8
74. Kawashima T, Kagawa S, Kobayashi N, et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 2004á10:285-92
75. Fujiwara T, Urata Y, Tanaka N. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter. Curr Cancer Drug Targets 2007á7:191-201
76. Hashimoto Y, Watanabe Y, Shirakiya Y, et al. Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus. Cancer Sci 2008á99:385-90
77. Sakai R, Kagawa S, Yamasaki Y, et al. Preclinical evaluation of differentially targeting dual virotherapy for human solid cancer. Mol Cancer Ther 2010 9:1884-93
78. Graat HC, Carette JE, Schagen FH, et al. Enhanced tumor cell kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53. Mol Cancer Ther 2007á6:1552-61
79. Tango Y, Fujiwara T, Itoshima T, et al. Adenovirus-mediated p14ARF gene transfer cooperates with Ad5CMV-p53 to induce apoptosis in human cancer cells. Hum Gene Ther 2002á13:1373-82
80. Itoshima T, Fujiwara T, Waku T, et al. Induction of apoptosis in human esophageal cancer cells by sequential transfer of the wild-type p53 and E2F-1 genes: Involvement of p53 accumulation via ARF-mediated MDM2 down-regulation. Clin Cancer Res 2000á6:2851-9
81. Gorospe M, Cirielli C, Wang X, et al. p21(Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells. Oncogene 1997á14:929-35
82. Idogawa M, Sasaki Y, Suzuki H, et al. A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells. Clin Cancer Res 2009á15:3725-32
83. Hasei J, Sasaki T, Tazawa H, et al. Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells. Mol Cancer Ther 2013á12:314-25
84. Fujiwara K, Daido S, Yamamoto A, et al. Pivotal role of the cyclin-dependent kinase inhibitor p21WAF1/CIP1 in apoptosis and autophagy. J Biol Chem 2008á283:388-97
85. Bouvet M, Ellis LM, Nishizaki M, et al. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 1998á58:2288-92
86. Nishizaki M, Fujiwara T, Tanida T, et al. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: A proposed mechanism for bystander effect. Clin Cancer Res 1999á5:1015-23
87. Waku T, Fujiwara T, Shao J, et al. Contribution of CD95 ligand-induced neutrophil infiltration to the bystander effect in p53 gene therapy for human cancer. J Immunol 2000á165:5884-90
88. Fukazawa T, Fujiwara T, Morimoto Y, et al. Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells. Oncogene 1999á18:2189- 99
89. van Beusechem VW, van Den Doel PB, Grill J, et al. Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res 2002á62:6165-71
90. Wang X, Su C, Cao H, et al. A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers. Mol Cancer Ther 2008á7:1598-603
91. Yamasaki Y, Tazawa H, Hashimoto Y, et al. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression. Eur J Cancer 2012á48:2282-91
92. Idema S, Lamfers ML, van Beusechem VW, et al. AdDelta24 and the p53-expressing variant AdDelta24-p53 achieve potent anti-tumor activity in glioma when combined with radiotherapy. J Gene Med 2007á9:1046-56
93. van Beusechem VW, van Den Doel PB, Gerritsen WR. Conditionally replicative adenovirus expressing degradation-resistant p53 for enhanced oncolysis of human cancer cells overexpressing murine double minute 2. Mol Cancer Ther 2005á4:1013-18
94. Su C, Cao H, Tan S, et al. Toxicology profiles of a novel p53-armed replicationcompetent oncolytic adenovirus in rodents, felids, and nonhuman primates. Toxicol Sci 2008á106:242-50
95. Nemunaitis J, Tong AW, Nemunaitis M, et al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther 2010 18:429-34
96. Suh SS, Yoo JY, Nuovo GJ, et al. MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme. Proc Natl Acad Sci USA 2012á109:5316-21
97. Wang J, Bucana CD, Roth JA, Zhang WW. Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytocidal effect of Ad5CMV-p53. Cancer Gene Ther 1995á2:9-17
98. Milas M, Yu D, Lang A, et al. Adenovirus-mediated p53 gene therapy inhibits human sarcoma tumorigenicity. Cancer Gene Ther 2000á7:422-9
99. Ternovoi VV, Curiel DT, Smith BF, Siegal GP. Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma. Lab Invest 2006á86:748-66
100. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007á445:661-5